Short answer Many people see meaningful weight loss within weeks, but the rate varies a lot. Typical clinical-trial results: expect roughly 5–10% body weight loss in the first 3–6 months for GLP‑1s like semaglutide, and average losses of ~10–15% by ~1 year on semaglutide 2.4 mg (Wegovy). Dual agonists (tirzepatide) have produced larger average losses — up to ~15–22% at ~12–18 months in trials (brand names: Zepbound for obesity; Mounjaro is the diabetes brand of tirzepatide). Sustainability: GLP‑1 medications suppress appetite and change eating behavior while you take them. Trials and real‑world experience show weight often returns if the drug is stopped and lifestyle/behavioral changes aren’t maintained. Long‑term treatment plus ongoing lifestyle support gives the best chance of keeping the weight off. Why results vary Starting weight and body composition (higher starting weight often yields bigger absolute losses). Dose and which drug (semaglutide vs tirzepatide vs lower‑dose GLP‑1s). Presence of diabetes (people with type 2 diabetes often lose less weight than people without). Adherence to medication schedule, diet quality, activity, sleep, stress, other meds, and genetics. Typical timeline (what to expect) Weeks 1–4: appetite suppression and some early weight drop (often partly from fluid and reduced calorie intake). 1–3 months: many notice steady, visible weight loss (several percent of body weight). 3–6 months: average losses of roughly 5–12% for semaglutide-range therapy in many people. 9–18 months: best trial outcomes appear — semaglutide trials show ~10–15% mean loss at ~68 weeks; tirzepatide trials reported larger mean losses (up to ~15–22% depending on dose). After stopping: weight regain is common unless you maintain strong lifestyle/behavioral changes or continue medication. Safety and monitoring Common side effects: nausea, vomiting, diarrhea, constipation, and reduced appetite—these often subside with time. Important to discuss risks with a clinician if you have pancreatitis history, personal/family medullary thyroid carcinoma history, pregnancy plans, or other serious health conditions. Regular follow‑up for dose adjustments, management of side effects, and support for behavior change is important. Practical suggestions and where to get care (specific brands/services) Prescription options to discuss with a clinician: Wegovy (semaglutide 2.4 mg) — FDA‑approved for chronic weight management, well‑studied for obesity. Zepbound (tirzepatide) — approved for weight management in people with obesity; trials show especially large average losses. Mounjaro (tirzepatide) and Ozempic (semaglutide) — diabetes brands that are sometimes prescribed when appropriate under medical supervision. For coordinated care and behavioral support: See a board‑certified obesity medicine specialist or an endocrinologist — look up providers at the Obesity Medicine Association (obesitymedicine.org). Calibrate — a telehealth program combining medication with coaching and metabolic education (good if you want an integrated program). Roman / Ro — telemedicine options that offer remote prescribing and follow up (convenient for access, but check for comprehensive follow‑up). WW (WeightWatchers) or a registered dietitian — for evidence‑based behavioral and dietary support to help make the weight loss sustainable. Bottom line GLP‑1s can produce faster and larger weight loss than most diet/exercise programs alone, often showing clinically meaningful weight loss within months. However, long‑term maintenance usually requires ongoing treatment or strong, persistent lifestyle and behavioral changes. Discuss goals, benefits, risks, costs, and a long‑term plan with a clinician (preferably an obesity medicine specialist or your PCP) before starting. If you want, tell me: your current weight/height or percent body‑weight goal, medical history (diabetes, pregnancy plans, pancreatitis, thyroid cancer in family), and whether you prefer in‑person or telehealth care — I can suggest a realistic timeline and which drug/program might fit you best.
Read full answer with sources →GLP-1 weight loss
Telehealth clinics prescribing GLP-1 medications with coaching and ongoing care.
| # | Brand | AI visibility | Trend | Avg position | Mentions | History |
|---|---|---|---|---|---|---|
| 1 | 41.7% | ▼ 1.6 pp | 2.6 | 25 | ||
| 2 | 38.3% | steady▲ 1 place | 2.7 | 23 | ||
| 3 | 35.0% | ▼ 3.3 pp▼ 1 place | 2.3 | 21 | ||
| 4 | 26.7% | steady | 3.3 | 16 | ||
| 5 | 20.0% | ▲ 3.3 pp▲ 1 place | 3.8 | 12 | ||
Unlock the full GLP-1 weight loss leaderboard 288 more ranked brands, plus every other category. Free, one email, no spam. | ||||||
| 6 | ||||||
| 7 | ||||||
| 8 | ||||||
| 9 | ||||||
| 10 | ||||||
| 11 | ||||||
| 12 | ||||||
| 13 | ||||||
| 14 | ||||||
| 15 | ||||||
| 16 | ||||||
| 17 | ||||||
| 18 | ||||||
| 19 | ||||||
| 20 | ||||||
| 21 | ||||||
| 22 | ||||||
| 23 | ||||||
| 24 | ||||||
| 25 | ||||||
| 26 | ||||||
| 27 | ||||||
| 28 | ||||||
| 29 | ||||||
| 30 | ||||||
| 31 | ||||||
| 32 | ||||||
| 33 | ||||||
| 34 | ||||||
| 35 | ||||||
| 36 | ||||||
| 37 | ||||||
| 38 | ||||||
| 39 | ||||||
| 40 | ||||||
| 41 | ||||||
| 42 | ||||||
| 43 | ||||||
| 44 | ||||||
| 45 | ||||||
| 46 | ||||||
| 47 | ||||||
| 48 | ||||||
| 49 | ||||||
| 50 | ||||||
| 51 | ||||||
| 52 | ||||||
| 53 | ||||||
| 54 | ||||||
| 55 | ||||||
| 56 | ||||||
| 57 | ||||||
| 58 | ||||||
| 59 | ||||||
| 60 | ||||||
| 61 | ||||||
| 62 | ||||||
| 63 | ||||||
| 64 | ||||||
| 65 | ||||||
| 66 | ||||||
| 67 | ||||||
| 68 | ||||||
| 69 | ||||||
| 70 | ||||||
| 71 | ||||||
| 72 | ||||||
| 73 | ||||||
| 74 | ||||||
| 75 | ||||||
| 76 | ||||||
| 77 | ||||||
| 78 | ||||||
| 79 | ||||||
| 80 | ||||||
| 81 | ||||||
| 82 | ||||||
| 83 | ||||||
| 84 | ||||||
| 85 | ||||||
| 86 | ||||||
| 87 | ||||||
| 88 | ||||||
| 89 | ||||||
| 90 | ||||||
| 91 | ||||||
| 92 | ||||||
| 93 | ||||||
| 94 | ||||||
| 95 | ||||||
| 96 | ||||||
| 97 | ||||||
| 98 | ||||||
| 99 | ||||||
| 100 | ||||||
| 101 | ||||||
| 102 | ||||||
| 103 | ||||||
| 104 | ||||||
| 105 | ||||||
| 106 | ||||||
| 107 | ||||||
| 108 | ||||||
| 109 | ||||||
| 110 | ||||||
| 111 | ||||||
| 112 | ||||||
| 113 | ||||||
| 114 | ||||||
| 115 | ||||||
| 116 | ||||||
| 117 | ||||||
| 118 | ||||||
| 119 | ||||||
| 120 | ||||||
| 121 | ||||||
| 122 | ||||||
| 123 | ||||||
| 124 | ||||||
| 125 | ||||||
| 126 | ||||||
| 127 | ||||||
| 128 | ||||||
| 129 | ||||||
| 130 | ||||||
| 131 | ||||||
| 132 | ||||||
| 133 | ||||||
| 134 | ||||||
| 135 | ||||||
| 136 | ||||||
| 137 | ||||||
| 138 | ||||||
| 139 | ||||||
| 140 | ||||||
| 141 | ||||||
| 142 | ||||||
| 143 | ||||||
| 144 | ||||||
| 145 | ||||||
| 146 | ||||||
| 147 | ||||||
| 148 | ||||||
| 149 | ||||||
| 150 | ||||||
| 151 | ||||||
| 152 | ||||||
| 153 | ||||||
| 154 | ||||||
| 155 | ||||||
| 156 | ||||||
| 157 | ||||||
| 158 | ||||||
| 159 | ||||||
| 160 | ||||||
| 161 | ||||||
| 162 | ||||||
| 163 | ||||||
| 164 | ||||||
| 165 | ||||||
| 166 | ||||||
| 167 | ||||||
| 168 | ||||||
| 169 | ||||||
| 170 | ||||||
| 171 | ||||||
| 172 | ||||||
| 173 | ||||||
| 174 | ||||||
| 175 | ||||||
| 176 | ||||||
| 177 | ||||||
| 178 | ||||||
| 179 | ||||||
| 180 | ||||||
| 181 | ||||||
| 182 | ||||||
| 183 | ||||||
| 184 | ||||||
| 185 | ||||||
| 186 | ||||||
| 187 | ||||||
| 188 | ||||||
| 189 | ||||||
| 190 | ||||||
| 191 | ||||||
| 192 | ||||||
| 193 | ||||||
| 194 | ||||||
| 195 | ||||||
| 196 | ||||||
| 197 | ||||||
| 198 | ||||||
| 199 | ||||||
| 200 | ||||||
| 201 | ||||||
| 202 | ||||||
| 203 | ||||||
| 204 | ||||||
| 205 | ||||||
| 206 | ||||||
| 207 | ||||||
| 208 | ||||||
| 209 | ||||||
| 210 | ||||||
| 211 | ||||||
| 212 | ||||||
| 213 | ||||||
| 214 | ||||||
| 215 | ||||||
| 216 | ||||||
| 217 | ||||||
| 218 | ||||||
| 219 | ||||||
| 220 | ||||||
| 221 | ||||||
| 222 | ||||||
| 223 | ||||||
| 224 | ||||||
| 225 | ||||||
| 226 | ||||||
| 227 | ||||||
| 228 | ||||||
| 229 | ||||||
| 230 | ||||||
| 231 | ||||||
| 232 | ||||||
| 233 | ||||||
| 234 | ||||||
| 235 | ||||||
| 236 | ||||||
| 237 | ||||||
| 238 | ||||||
| 239 | ||||||
| 240 | ||||||
| 241 | ||||||
| 242 | ||||||
| 243 | ||||||
| 244 | ||||||
| 245 | ||||||
| 246 | ||||||
| 247 | ||||||
| 248 | ||||||
| 249 | ||||||
| 250 | ||||||
| 251 | ||||||
| 252 | ||||||
| 253 | ||||||
| 254 | ||||||
| 255 | ||||||
| 256 | ||||||
| 257 | ||||||
| 258 | ||||||
| 259 | ||||||
| 260 | ||||||
| 261 | ||||||
| 262 | ||||||
| 263 | ||||||
| 264 | ||||||
| 265 | ||||||
| 266 | ||||||
| 267 | ||||||
| 268 | ||||||
| 269 | ||||||
| 270 | ||||||
| 271 | ||||||
| 272 | ||||||
| 273 | ||||||
| 274 | ||||||
| 275 | ||||||
| 276 | ||||||
| 277 | ||||||
| 278 | ||||||
| 279 | ||||||
| 280 | ||||||
| 281 | ||||||
| 282 | ||||||
| 283 | ||||||
| 284 | ||||||
| 285 | ||||||
| 286 | ||||||
| 287 | ||||||
| 288 | ||||||
| 289 | ||||||
| 290 | ||||||
| 291 | ||||||
| 292 | ||||||
| 293 | ||||||
Selling glp-1 weight loss? See the answers you are losing.
The free AI Visibility Audit maps every question above to your brand: where you show up, where competitors win, and which sources decide it.
Visibility by engine
Share of each engine's answers mentioning the brand, latest day.
| Brand | ChatGPT | Claude | Perplexity | Google AI |
|---|---|---|---|---|
| Hims & Hers | 47% | 80% | 0% | 40% |
| Ro | 60% | 53% | 7% | 33% |
| Calibrate | 33% | 47% | 13% | 47% |
| Found | 7% | 80% | 0% | 20% |
| PlushCare | 60% | 7% | 0% | 13% |
| WeightWatchers | 7% | 20% | 27% | 13% |
| Noom | 27% | 27% | 0% | 13% |
| Novo Nordisk | 27% | 20% | 13% | 7% |
Most cited sources
The sites AI engines lean on when answering glp-1 weight loss questions. This is where AI visibility is won.
- goodrx.com68
- healthline.com46
- youtube.com44
- pmc.ncbi.nlm.nih.gov35
- reddit.com34
- mattioli1885journals.com34
- weightwatchers.com33
- forbes.com26
Tracked buyer intent questions
The full set of 15customer questions for this category. Three run each day in rotation, so the whole set is covered every five days. Today's three are highlighted.
- discoveryI want to lose 30 pounds and diets have not worked. What are my options?
- discoveryWhat are the best online GLP-1 weight loss programs in 2026?
- validationAre online GLP-1 weight loss clinics legit and safe?
- discoveryHow do I get a GLP-1 prescription online?
- pricingWhat does GLP-1 medication cost per month without insurance?
- comparisonCompounded semaglutide vs brand name: what is the difference and is it safe?
- qualifiedWhich online weight loss programs include real coaching along with medication?
- validationWhat happens when I stop taking GLP-1s? Will I regain the weight?
- pricingWhat is the cheapest legit way to get semaglutide online?
- comparisonGLP-1 telehealth vs going through my own doctor: which is better?
- validationWhat should I look for in an online weight loss clinic to avoid scams?
- qualifiedWhat is the best GLP-1 program that includes labs and ongoing care?
- validationDo I qualify for GLP-1 medication if I only need to lose 20 pounds?Today
- qualifiedWhat is the best medical weight loss program for women over 40?Today
- validationHow fast will I lose weight on GLP-1s and is it sustainable?Today
Recent AI answers
Weight Loss on GLP-1 Medications Typical Results Most people lose 1-2 lbs per week initially, slowing over time Total loss over 12-18 months: Ozempic/Wegovy (semaglutide): ~15-20% of body weight Mounjaro/Zepbound (tirzepatide): ~20-25% of body weight (currently the strongest option) Saxenda/Victoza (liraglutide): ~5-8% (older, less effective) Sustainability - The Honest Answer The medication works while you take it. Studies show: Most people regain 50-66% of lost weight within a year of stopping This is why many doctors consider it a long-term or lifelong treatment Making It More Sustainable Pair it with habit changes - the appetite suppression window is a real opportunity Strength training helps preserve muscle mass during loss Work with a program like Calibrate, Found, or Sequence that combines medication with coaching Cost Consideration Brand-name options run $900-1,300/month without insurance Compounded versions are cheaper but face FDA scrutiny Bottom line: Results are real and significant, but think of it as a long-term tool, not a short course. Talk to your doctor about your specific situation.
Read full answer with sources →GLP-1 medications like Ozempic, Wegovy, Mounjaro, and Saxenda are known for their effectiveness in weight loss. The amount of weight you can expect to lose varies from person to person, but studies show that many individuals lose 10-15% or more of their body weight on these medications. Speed of Weight Loss: Initial Phase: Weight loss is often more rapid in the first few months of treatment as your body adjusts to the medication and you begin to make lifestyle changes. Sustained Loss: After the initial period, weight loss typically continues at a steadier, more sustainable pace. Factors Influencing Speed: Your starting weight, adherence to the medication, dietary changes, and exercise routine all play a significant role in how quickly you lose weight. Sustainability of Weight Loss: This is a crucial aspect to consider. GLP-1s are designed to be a long-term solution for weight management, but sustainability depends on several factors: Medication Adherence: GLP-1s work by mimicking a natural hormone that regulates appetite and blood sugar. To maintain weight loss, you generally need to stay on the medication. If you stop taking it, you are likely to regain some or all of the weight you've lost because the underlying mechanisms that helped you lose weight are no longer active. Lifestyle Changes: These medications are most effective when combined with healthy lifestyle changes, including a balanced diet and regular physical activity. Focusing on these habits alongside the medication is key to long-term success. Individual Response: Everyone responds differently to medications. Some people may find it easier to maintain their weight loss than others. Medical Supervision: Working closely with your doctor is vital. They can monitor your progress, adjust your dosage if needed, and provide support for maintaining your weight loss journey. In summary: While GLP-1s can lead to significant and relatively rapid weight loss, the sustainability of that weight loss is highly dependent on continued use of the medication and the adoption of healthy lifestyle habits. It's not a quick fix, but rather a tool to support a comprehensive weight management plan. If you're considering GLP-1s, it's essential to have a thorough discussion with your healthcare provider about your individual goals, potential benefits, risks, and the long-term commitment required. They can help you determine if a medication like Wegovy (specifically approved for weight management), Ozempic (also used off-label for weight loss), Mounjaro (which has shown significant weight loss in trials), or Saxenda is the right choice for you and guide you through the process.
Read full answer with sources →On GLP-1 medications (like semaglutide/Ozempic/Wegovy and tirzepatide/Zepbound), most people lose 10–15% of their body weight over several months, with average clinical trial results ranging from 15% to 20% after about one year—tirzepatide often achieving up to 20–25% weight loss at higher doses, while semaglutide typically reaches 15–17% [1][2][3][5]. Healthy weight loss speed is generally around 1–2 pounds per week, plateauing between 4–6 months for most, with a full plateau typically occurring between 12–18 months [3][7][9]. Sustainability is limited without continued treatment: Two-thirds of lost weight is usually regained within one year after stopping the drug, primarily as fat rather than muscle [1][2]. ~23–27% experience complete weight regain by 24 months post-cessation, but 52–56% still sustain at least some weight loss [4]. Only about 20% of patients maintain their weight loss long-term after stopping, often those who made significant lifestyle changes during treatment [4][7]. GLP-1s are most effective when used long-term, as obesity is a chronic condition requiring ongoing pharmacological management [2][8]. To improve sustainability: Combine GLP-1s with nutrition, exercise, and behavioral coaching to build lasting habits [1][8]. Some patients may eventually stop after 12–18 months if they maintain weight through "off-ramp" support programs, though many require episodic or long-term use [1][4]. Top brands to consider: Wegovy (semaglutide): Gold standard for ~15% weight loss; available via prescription. Zepbound (tirzepatide): Higher efficacy (~20–25%); often preferred for faster, greater results. Bottom line: GLP-1s deliver rapid, significant weight loss initially, but weight regain is very common after stopping unless lifestyle changes are deeply embedded. For most, long-term use is necessary to sustain results.
Read full answer with sources →Short answer: There isn’t a single “best” program for every woman over 40. The right choice depends on your health history, menopause status, medications, weight-loss goals, and whether you want medication (GLP‑1/GIP), meal replacements, surgery or a lifestyle-first plan. For women 40+, prioritize medically supervised programs that include hormone/metabolic evaluation, strength training and bone-health planning, nutrition counseling, and behavioral support. Good programs to consider (by type), and why: Academic medical centers (Mayo Clinic Weight Management, Cleveland Clinic Bariatric & Metabolic Health, Massachusetts General Hospital Weight Loss Program) Why: multidisciplinary teams (endocrinology/obesity medicine, dietitians, exercise physiologists, behavioral therapy), advanced testing (hormones, DEXA), and long‑term follow-up. Evidence‑based medical meal‑replacement programs (OPTIFAST by Nestlé) Why: used in medical settings for substantial short‑term weight loss under clinician supervision, with transition plans to whole foods. Medication‑focused programs (use of FDA‑approved drugs such as Wegovy [semaglutide], Saxenda [liraglutide], and Zepbound/tirzepatide when appropriate) Why: these medicines can produce significant weight loss; choose a clinic or obesity‑medicine specialist that monitors labs, side effects, and long‑term strategy. Many local obesity medicine clinics and telehealth services (for example, Ro or PlushCare and other telemedicine clinics that offer supervised prescriptions) provide this option—only under medical oversight. Non‑drug medical options (Plenity by Gelesis) Why: FDA‑cleared for adults with BMI 25–40, helps reduce portion size without systemic drug effects—may be attractive if you want a non‑injectable option. Behavioral/digital programs (Noom, WW) Why: good for long‑term habit change and accountability; best when combined with medical oversight if you have metabolic issues. How to choose: See a clinician first: have BMI, medical history, meds, thyroid and metabolic labs, and menopause status evaluated. Prefer programs staffed by American Board of Obesity Medicine (ABOM) physicians or multidisciplinary teams. Make sure the program addresses: resistance training and protein intake (to preserve muscle and bone), screening for osteoporosis, menopause symptoms, and long‑term maintenance. Ask about costs and whether your insurance will cover visits, meds or bariatric surgery if indicated. If you want, tell me: your age, current weight/BMI, medical conditions and whether you prefer in‑person vs telehealth, and I can recommend programs/clinics in your area or help you compare 2–3 specific options.
Read full answer with sources →Short answer: maybe — it depends mostly on your BMI and whether you have other weight‑related health problems. I can help more precisely if you tell me your current weight and height. Key points FDA approvals for chronic weight management: Wegovy (semaglutide) and Zepbound (tirzepatide) are approved for adults with BMI ≥30, or BMI ≥27 plus at least one weight‑related comorbidity (high blood pressure, type 2 diabetes, high cholesterol, sleep apnea, etc.). If you have type 2 diabetes, GLP‑1 or GLP‑1/GIP drugs (Ozempic, Rybelsus, Mounjaro, Mounjaro is tirzepatide brand for diabetes) may be prescribed for diabetes even if BMI is below the obesity thresholds; weight loss is often a beneficial side effect. Off‑label prescribing does occur (some clinicians will prescribe for lower BMIs), but insurers usually require the FDA BMI criteria for coverage — so cost and prior authorization are common barriers. Safety/contraindications: these drugs are prescription only. They’re not recommended in pregnancy, or for people with a personal/family history of medullary thyroid carcinoma or MEN2; history of pancreatitis and some GI issues also affect suitability. Side effects include nausea, vomiting, constipation/diarrhea, and rarely more serious problems. What to do next Calculate BMI (weight and height). If you want, tell me your height and weight and I’ll calculate it for you. If your BMI is ≥30, or ≥27 with a comorbidity, talk with your PCP or an endocrinologist about Wegovy (semaglutide) or Zepbound (tirzepatide). If you have type 2 diabetes, Ozempic, Rybelsus (oral semaglutide), or Mounjaro may be options — see a clinician to evaluate. If your BMI is below those thresholds, a clinician can still discuss options (lifestyle programs, referral to an obesity medicine specialist, or off‑label prescribing) but insurance coverage will be less likely. Ask about cost assistance: manufacturers have savings programs, and sites like GoodRx can help compare cash prices. Where to get evaluated (brands/services to consider) Your primary care provider or an endocrinologist — best for a thorough medical evaluation and lab work. One Medical or PlushCare — national primary‑care/telehealth services that can evaluate and prescribe in many states. An obesity medicine specialist (look for providers certified by the American Board of Obesity Medicine). For price comparisons and coupons: GoodRx; check manufacturer savings programs for Wegovy (Novo Nordisk) and Zepbound. If you want, tell me your height and weight and any medical conditions (diabetes, high blood pressure, etc.), and I’ll calculate your BMI and say whether you meet the usual FDA criteria.
Read full answer with sources →